Researchers at Yale Cancer Center showed that inhibition of the CECR2 gene prevents triple-negative breast cancer from advancing or metastasizing.
A recent study from cancer researchers at the University of Alabama at Birmingham and Georgia State University has identified a new therapeutic target in quadruple-negative breast cancer, or QNBC, one of the deadliest and most aggressive treatment-resistant forms of breast cancer.
